A multicentre study assessed toxicity and survival end points following dose-escalated prostate stereotactic body radiotherapy (SBRT) in 309 patients with low-risk or intermediate-risk prostate cancer. At a median follow-up period of 61 months, rates of grade 3 or higher genitourinary adverse events (AEs) were low (1.3%), and no grade 4 or 5 AEs occurred. The 5-year overall survival and biochemical disease-free survival compared favourably to historical controls.
References
Original article
Meier, R. M. et al. Multi-center trial of stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int. J. Radiat. Oncol. Biol. Phys. https://doi.org/10.1016/j.ijrobp.2018.05.040 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bradley, C.A. SBRT suitable for early-stage disease. Nat Rev Urol 15, 526 (2018). https://doi.org/10.1038/s41585-018-0050-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-018-0050-9